Description
Description
Victoza® (liraglutide) is considered an injectable incretin mimic. Type 2 diabetes is treated with this relatively new drug. A common mistake is to confuse it with dulaglutide or semaglutide.
Type 2 diabetes mellitus in adults and children 10 years of age and older can be controlled with Victoza® and diet and exercise.
To improve glycaemic control, it is usually used in conjunction with diet and lifestyle changes in adults and children with type 2 diabetes.
A number of studies have shown that incretin mimetics lower blood glucose levels. In combination with diet and exercise, this supplement has also been shown to be beneficial for weight loss when compared to placebo subjects.
Victoza® was first approved by the FDA for use in adults with type 2 diabetes in 2010 and in children over ten years of age with type 2 diabetes in 2019. The FDA has approved it for pediatric use for the first time since metformin was approved for pediatric use in 2000, which made it the only non-insulin drug approved for pediatric use.
Victoza® is also associated with Trulicity®, Saxenda®, and Rybelsus®, which all have become common among the weight loss communities.
It is important to note that Victoza® does not comes with needles.
Warnings
Warnings
If you have hypoglycaemia or need to be alert for projects, do not drive.
The medication course should not be taken with excessive alcohol consumption.
Hypoglycemia is more prevalent in children (especially those under ten years of age). As a result, it is important to monitor blood sugar levels on a regular basis.
The symptoms of acute pancreatitis should be recognized and treated immediately.
Take precautions to avoid fluid depletion and avoid dehydration associated with gastrointestinal side effects
Cholelithiasis and cholecystitis should be recognized by their symptoms. This disease is characterized by fever, jaundice (which indicates elevated levels of bilirubin), pain in the right adjacent area of the stomach, and nausea.
The following signs and symptoms should be monitored by your healthcare provider in order to identify any neoplastic growth as soon as possible. Since thyroid-related cancer is a significant concern with Victoza® use, your healthcare provider will pay attention to these signs and symptoms.
Usage
Usage
Before taking Victoza, tell your healthcare provider if you:
-have any of the conditions listed in the section “What is the most important information I should know about Victoza?”
-are allergic to liraglutide or any of the other ingredients in Victoza.
-have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
-have or have had kidney or liver problems, have any other medical conditions, are pregnant or plan to become pregnant. It is not known if Victoza will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking Victoza.
-are breastfeeding or plan to breastfeed. It is not known if Victoza passes into your breast milk. You and your healthcare provider should decide if you will take Victoza or breastfeed. You should not do both without talking with your healthcare provider first.
Tell your healthcare provider about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Victoza slows stomach emptying and can affect medicines that need to pass through the stomach quickly. Victoza may affect the way some medicines work and some other medicines may affect the way Victoza works.
Tell your healthcare provider if you take other diabetes medicines, especially sulfonylurea medicines or insulin. Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist each time you get a new medicine.
Before Taking Victoza
Before Taking Victoza
Before taking Victoza®, tell your healthcare provider if you:
A person who is allergic to liraglutide or any of the other ingredients in Victoza® should not take this medicine.
When your stomach is having severe problems, such as slow emptying (gastroparesis) or problems digesting your food, you may need to see a doctor
Are pregnant or plan to become pregnant, have kidney or liver problems, or have any other medical conditions. Unborn babies are not known to be affected by Victoza®. During treatment with Victoza®, tell your healthcare provider if you become pregnant.
A breastfeeding mother or a mother who plans to breastfeed a child. Victoza may pass into your breast milk. Victoza® or breastfeeding should be discussed with your healthcare provider. A healthcare provider should be consulted before you do both.
Tell your healthcare provider about all the medicines you take, including prescriptions, non-prescriptions, vitamins, and herbal supplements. A medicine that needs to pass through the stomach quickly can be affected by Victoza®, which slows stomach emptying. Some medicines may interact with Victoza®, and some medicines may interact with Victoza®.
Do not take other diabetes medicines, including sulfonylureas or insulin, without first consulting your healthcare provider. Make sure you are aware of the medicines you take. Each time you get a new medicine, keep a list of them with you to show your healthcare provider and pharmacist.
Common Side Effects
Common Side Effects
There are mild and severe side effects associated with Victoza®. You will experience the following side effects while taking Victoza®. There may, however, be other side effects not listed here. Find out more about Victoza®’s potential side effects by talking to your doctor or one of our pharmacist.
It is common for people to experience nausea (the most common side effect), vomiting, constipation, diarrhea, dizziness, dry mouth, gallbladder disorders (cholelithiasis or cholecystitis), gastrointestinal discomfort, gastrointestinal disorders, insomnia, and altered taste.
Severe Side Effects
Severe Side Effects
Pancreatitis and thyroid tumors are two of Victoza®’s most serious side effects.
Thyroid Tumors
There is a possibility that Victoza® can cause thyroid tumours, including cancer. It was discovered that the medicine in Victoza® caused tumors in the thyroid glands of rats and mice during the drug testing process. There were some cancerous tumors among these tumors. People taking Victoza® are not known to develop thyroid tumors or medullary thyroid cancer. Detecting and treating medullary thyroid cancer early can prevent death. Surgically removing your thyroid may be required if you develop thyroid tumors or cancer.
Tell your healthcare provider if you or anyone in your family has had thyroid cancer, especially medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.
Victoza® should not be taken if you have medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. Victoza® should not be used by people with these conditions as they are already at a higher risk of developing medullary thyroid cancer in general.
If you experience a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath while taking Victoza®, contact your healthcare provider. Thyroid cancer may cause these symptoms.
Pancreatitis
Victoza® can also cause inflammation of the pancreas, which can be severe and cause death. If you have a family history of pancreatitis or are experiencing any symptoms, speak with your healthcare provider.
Allergic Reaction
Allergic Reaction
Victoza® may cause an allergic reaction if you have any allergies. Tell your healthcare provider if you have any allergies.
Victoza® contains liraglutide as its active ingredient. Water for injection and propylene glycol are the inactive ingredients.
Storage
Storage
Before use:
Victoza® pens should be stored in the refrigerator between 36°F and 46°F (2°C and 8°C). Victoza® should not be frozen or used if it has been frozen. Victoza® should not be stored near the refrigerator cooling element.
Pen in use:
Victoza® pens should be stored in a refrigerator between 36°F and 46°F (2°C to 8°C) for 30 days. The pen should be stored at a temperature between 59oF and 86oF (15oC to 30oC) when carried away from home.
Victoza® should be discarded if it has been exposed to temperatures over 86oF (30oC). Keep your Victoza® pen’s cap on when not in use to protect it from heat and sunlight.
Victoza® pens should be used within 30 days after they are stored outside the refrigerator for the first time. If there is any medicine left in the Victoza® pen after these 30 days, throw it away. If the expiration date on Victoza®’s carton has passed, do not use it
The Victoza® pen should not be stored with the needle attached. The needle should always be safely removed and disposed of after each injection. As a result, contamination, infection, and leakage may be prevented. Getting the right dose of Victoza is also important. You can find information about how to dispose of used pen needles and used Victoza® pens in the Patient Instructions for Use.
